This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Endocrine/metabolic disease				
Diabetes	Fibroblast growth factor receptor 1 (FGFR1; CD331); klotho- β (KLB); fibroblast growth factor 21 (FGF21)	<p><i>In vitro</i> and nonhuman primate studies identified an agonistic mAb of the FGFR1-KLB complex that could help treat type 2 diabetes. <i>In vitro</i> screening of antibodies from humanized mice identified an antibody that specifically bound to and agonized the FGFR1-KLB complex, which is a target of FGF21 expressed in adipocytes. In obese monkeys, the antibody decreased body weight, BMI, insulin resistance and triglyceride levels compared with vehicle. Next steps at Amgen Inc. include longer-term preclinical studies.</p> <p>Ambrx Inc. and Bristol-Myers Squibb Co. have ARX618, a stabilized form of FGF21, in preclinical development for type 2 diabetes. Roche's Genentech Inc. has an agonistic antibody that targets FGFR1 in preclinical development for the same indication.</p> <p>SciBX 5(49); doi:10.1038/scibx.2012.1282 Published online Dec. 20, 2012</p>	Patent application filed; licensing status undisclosed	<p>Foltz, I.N. <i>et al. Sci. Transl. Med.</i>; published online Nov. 28, 2012; doi:10.1126/scitranslmed.3004690</p> <p>Contact: Yang Li, Amgen Inc., South San Francisco, Calif. e-mail: yangl@amgen.com</p>